Yang Xiaoming: China's new crown vaccine is "not only leading in speed, but also good in quality"

Xinhua News Agency, Shenzhen, April 24 (Reporter Zhao Ruixi) "China has used the strength of the whole country to complete the research and development of the new crown vaccine" and "not only is it leading in speed, but also in quality, and it is at the forefront of the world." Yang Xiaoming, chairman of Sinopharm China Biotechnology Co., Ltd., said at the "Shenzhen Forum" of the 19th China International Talent Exchange Conference held on the 24th.

Yang Xiaoming said that the vaccine industry, as part of the biomedical industry, is an industry that must rely on scientific and technological innovation to continue to develop. China's vaccine innovation has experienced a process from "following and running" to "running together" to "leading". Vaccine innovation is a long and difficult process, and there are three core problems of long time, high investment and low success rate in the development of innovative vaccines. In the face of the new crown pneumonia epidemic, China has mobilized the strength of the whole country to quickly develop an inactivated new crown vaccine in only 98 days, "not only leading in speed, but also good in quality, walking in the forefront of the world." At present, There are 10 NEW CROWN vaccines in China that have entered Phase III clinical trials, which are not only numerous, but also have a relatively complete technical route and rapid progress. Moreover, among the 11 vaccines that have been approved for emergency use in various places around the world, Chinese vaccines account for 5, reflecting China's leading position in the research and development of new crown vaccines.

He said that China's new crown inactivated vaccine not only goes fast, the safety and efficacy of the product are very good, and the supply is very large. Sinopharm's Bio-COVID-19 inactivated vaccine has been approved for marketing in 5 countries and approved for use in 62 countries.

Yang Xiaoming said that in recent years, with the improvement of the technical level, The innovation of Chinese vaccine varieties has accelerated, in addition to the new crown inactivated vaccine, the recombinant hepatitis E vaccine, hand-foot-and-mouth disease (EV71) vaccine, Ebola vaccine and so on are also China's original vaccines. The global vaccine variety covers about 41 infectious diseases, and China can produce its own vaccine to prevent 36 diseases, making it one of the few countries in the world that can rely on its own capacity to solve the problem of immunization supply and vaccination.

Source: Xinhua Net